Med. praxi. 2025;22(1):27-29

Estrogenic treatment and liver functions

doc. MUDr. Jiří Slíva, Ph.D., MBA
Ústav farmakologie, 3. LF UK, Praha

Estrogens are key hormones that play a vital role in the physiology of the reproductive system in women. However, their therapeutic use in hormonal treatment, contraception and the treatment of hormone-dependent diseases may be associated with a number of side effects, especially on the liver. This article focuses on the mechanisms of action of estrogens and their potential hepatotoxic effects, as well as risk factors and possible differences between representatives.

Keywords: estrogens, estradiol, estetrol, ethinyl estradiol, liver, safety, side effects.

Published: February 20, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slíva J. Estrogenic treatment and liver functions. Med. praxi. 2025;22(1):27-29.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF

    References

    1. Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005 Sep 28;227(2):115-24. doi: 10.1016/j.canlet.2004. 10. 007. Epub 2004 Nov 19. PMID: 16112414. Go to original source...
    2. Lee AJ, Cai MX, Thomas PE, et al. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98. doi: 10.1210/en.2003-0192. PMID: 12865317. Go to original source... Go to PubMed...
    3. Zhang H, Cui D, Wang B, et al. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet. 2007;46(2):133-57. doi: 10.2165/00003088-200746020-00003. PMID: 17253885. Go to original source... Go to PubMed...
    4. Rodrigues AD. Drug Interactions Involving 17α-Ethinylestradiol: Considerations Beyond Cytochrome P450 3 A Induction and Inhibition. Clin Pharmacol Ther. 2022 Jun;111(6):1212-1221. doi: 10.1002/cpt.2383. Epub 2021 Aug 24. PMID: 34342002. Go to original source... Go to PubMed...
    5. Rose DP, Goldman M, Connolly JM, Strong LE. High-fiber diet reduces serum estrogen concentrations in premenopausal women. Am J Clin Nutr. 1991 Sep;54(3):520-5. doi: 10.1093/ajcn/54. 3. 520. PMID: 1652197. Go to original source...
    6. Harrington WR, Sengupta S, Katzenellenbogen BS. Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells. Endocrinology. 2006 Aug;147(8):3843-50. doi: 10.1210/en.2006-0358. Epub 2006 May 11. PMID: 16690804. Go to original source... Go to PubMed...
    7. Rodrigues AD. Drug Interactions Involving 17α-Ethinylestradiol: Considerations Beyond Cytochrome P450 3A Induction and Inhibition. Clin Pharmacol Ther. 2022 Jun;111(6):1212-1221. doi: 10.1002/cpt.2383. Epub 2021 Aug 24. PMID: 34342002. Go to original source... Go to PubMed...
    8. Raps M, Helmerhorst F, Fleischer K, et al. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives. J. Thromb. Haemost. 2012;10:992-997. doi: 10.1111/j.1538-7836.2012.04720.x. Go to original source... Go to PubMed...
    9. Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet. Gynecol. Scand. 2002;81:482-490. doi: 10.1034/j.1600-0412.2002.810603.x. Go to original source...
    10. Mawet M, Maillard C, Klipping C, et al. Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives. Eur. J. Contracept. Reprod. Health Care. 2015;20:463-475. doi: 10.3109/13625187.2015.1068934. Go to original source... Go to PubMed...
    11. Klipping C, Duijkers I, Mawet M, et al. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception. 2021;103:213-221. doi: 10.1016/j.contraception.2021. 01. 001. Go to original source...
    12. Kluft C, Zimmerman Y, Mawet M, et al. Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol. Contraception. 2017;95:140-147. doi: 10.1016/j.contraception.2016. 08. 018. Go to original source...
    13. Douxfils J, Klipping C, Duijkers I, et al. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters. Contraception. 2020;102:396-402. doi: 10.1016/j.contraception.2020. 08. 015. Go to original source...
    14. Arnal JF, Scarabin PY, Trémollières F, et al. Estrogens in vascular biology and disease: Where do we stand today? Curr. Opin. Lipidol. 2007;18:554-560. doi: 10.1097/MOL.0b013e3282ef3bca. Go to original source... Go to PubMed...
    15. Hodgin JB, Krege JH, Reddick RL, et al. Estrogen receptor α is a major mediator of 17β-estradiol's atheroprotective effects on lesion size in Apoe-/- mice. J. Clin. Investig. 2001;107:333-340. doi: 10.1172/JCI11320. Go to original source... Go to PubMed...
    16. Coelingh Bennink HJT, Verhoeven C, Zimmerman Y, et al. Pharmacodynamic effects of the fetal estrogen estetrol in postmenopausal women: Results from a multiple-rising-dose study. Menopause. 2017;24:677-685. doi: 10.1097/GME.0000000000000823. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.